Analog Devices Receives FDA Approval for Sensinel™ Cardiopulmonary Management System

Analog Devices (ADI) has received the US FDA 510(k) clearance of the Sensinel™ Cardiopulmonary Management (CPM) System, a non-invasive, remote management system that captures cardiopulmonary measurements for chronic disease management such as heart failure.

The Sensinel CPM System is equipped with a suite of physiological indicators to help care teams better manage chronic conditions early, remotely and accurately. Patients self-apply ADI’s Sensinel CPM Wearable which they only wear for three to five minutes in a home care setting. The device then captures data about their cardiopulmonary health. This data is automatically uploaded to ADI’s Sensinel CPM Cloud Platform using a cellular link (without the need for a patient-supplied Internet connection) and is then further analyzed using ADI’s Sensinel CPM Intelligent Algorithms in the cloud.

By combining our wearable vital signs sensing and signal processing technology with cardiologist-inspired algorithms to precisely determine a congestive heart failure patient’s daily state of health, we developed the Sensinel CPM System,” said Patrick O’Doherty, Senior Vice President of Digital Healthcare at ADI.

Our new cardiopulmonary system is designed to fit seamlessly into the care workflow, providing a variety of physiological measurements that enable care teams to make early clinical decisions without being overwhelmed by information,” said Dr Venu Gopinathan, ADI Fellow and Managing Director of Medical Products at ADI.

To view the source version, please click HERE.